# A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Source: https://onco.cc/trials/nct03635983/  
OnCo record `nct03635983` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Bristol-Myers Squibb, completed.

## Summary

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma is a phase 3 interventional study registered as NCT03635983 by Bristol-Myers Squibb, with 783 participants recorded, started 2018-09-21 and reaching its primary completion in 2021-11-19. Interventions recorded: NKTR-214, Nivolumab. Conditions recorded: Melanoma.

Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03635983
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
- Sponsor: Bristol-Myers Squibb
- Enrolled: 783

## Sources

- ClinicalTrials.gov NCT03635983: https://clinicaltrials.gov/study/NCT03635983

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Bempegaldesleukin](https://onco.cc/drugs/bempegaldesleukin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct03635983.json